Biofrontera Inc. (NASDAQ:BFRI) Sees Significant Increase in Short Interest

Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 189,627 shares, a growth of 83.8% from the October 15th total of 103,148 shares. Based on an average trading volume of 146,358 shares, the days-to-cover ratio is presently 1.3 days. Currently, 1.4% of the company’s stock are sold short.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Wall Street Zen lowered shares of Biofrontera from a “buy” rating to a “hold” rating in a research note on Sunday, September 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Biofrontera in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce”.

Get Our Latest Analysis on Biofrontera

Institutional Trading of Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. AIGH Capital Management LLC boosted its stake in shares of Biofrontera Inc. (NASDAQ:BFRI – Free Report) by 102.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,496,583 shares of the company’s stock after purchasing an additional 756,673 shares during the quarter. AIGH Capital Management LLC owned approximately 10.08% of Biofrontera worth $1,616,000 at the end of the most recent reporting period. 10.08% of the stock is currently owned by institutional investors and hedge funds.

Biofrontera Stock Performance

NASDAQ:BFRI traded down $0.23 during trading hours on Friday, reaching $0.70. 875,774 shares of the stock were exchanged, compared to its average volume of 148,265. The stock has a market capitalization of $10.40 million, a P/E ratio of -1.56 and a beta of 0.88. The firm has a 50 day simple moving average of $1.02 and a 200-day simple moving average of $1.03. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.78. Biofrontera has a 52 week low of $0.55 and a 52 week high of $1.66.

Biofrontera (NASDAQ:BFRI – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.31). Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The firm had revenue of $9.07 million during the quarter, compared to the consensus estimate of $8.50 million.

Biofrontera Company Profile

(Get Free Report)

Biofrontera Inc. is a biopharmaceutical company focused on dermatology and the commercial development of prescription products for treating skin conditions. Its business is primarily centered on the U.S. market. The company’s main product is Ameluz, a topical gel containing aminolevulinic acid hydrochloride. It is used with Biofrontera’s BF-RhodoLED light device in photodynamic therapy to treat certain actinic keratoses, precancerous lesions that can develop on sun-damaged skin. Biofrontera’s products combine a topical treatment with a specialized light source, which activates the treatment during a clinical procedure.

Featured Stories

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.